FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135926707> ?p ?o ?g. }

• W3135926707 endingPage "S604" @default.
• W3135926707 startingPage "S603" @default.
• W3135926707 abstract "There is currently limited knowledge of resistant mechanisms after failure of Osimertinib treatment in T790M-positive NSCLC in Asia. We used Non-Invasive Molecular Testing (NIMT) to explore the acquired resistant mechanisms to Osimertinib and their clinical relevancies. This study was performed from January 2016 to December 2019 in T790M-positive NSCLC patients who received Osimertinib after failure of 1st/2nd generation EGFR-TKI treatment in Ramathibodi Hospital lung cancer database. We included patients who had plasma samples before treatment and at disease progression. The paired plasma samples were analyzed for resistant mechanisms by NGS (Thermofisher Pancancer 52 genes) then correlated with clinical outcomes. The 100 plasma samples from 50 patients were included (17 Males; 33 Females). The median age was 63.5 year-old. The majority of patients were non-smoker (82%) and adenocarcinoma (98%). Types of preexisting mutations were exon 19 deletion (60%), and exon 21 L858R (32%). Most of the patients used Osimertinib as 2nd-line treatment (68%). The response rates were 52% PR, 34% SD, and 14% PD. Nineteen patients (38%) developed more than one resistant alteration. The T790M-loss was most commonly found (50%), followed by PIK3CA (14%), EGFR C797S / HER2 / FGFR2 mutation (10% of each mutation) and EGFR (L792F, P848L/Q)/ BRAF/ RET/ KIT mutation (8% of each mutation), MET mutation (6%), MET exon 14 skipping (4%), MET amplification (2%) and small cell transformation (2%), and so on. EGFR C797S was found only in T790M-maintained patients. The median time to treatment failure (TTF) for taking Osimertinib in all patients was 9.3 mo. The patients with T790M-loss tended to have shorter TTF than the patients with T790M-maintained [median TTF 6.0 vs 10.1 months (mo), P=0.21]. Patients who developed T790M-maintained with C797S had tended of shorter OS compared to T790M-maintained without C797S (11.0 vs 15.2 mo). Furthermore, patients with T790M-loss together with other co-mutations had shorter TTF compared to patients with T790M-loss without other co-mutations (4.1 vs. 10.6 mo, adjusted HR 5.38, P=0.07) (Figure1). The patient who had brain metastasis before using Osimertinib significantly related to T790M-loss and patient who developed brain progression was related to BRAF mutation. There were heterogeneous mechanisms of acquired resistance to Osimertinib in T790M-positive NSCLC. The patient with T790M-loss tended to have poorer survival compared to T790M-maintained patients. C797S and T790M loss with other co-mutation are the important factors affected the survival outcomes in this group of patients." @default.
• W3135926707 created "2021-03-29" @default.
• W3135926707 creator A5000749939 @default.
• W3135926707 creator A5008073664 @default.
• W3135926707 creator A5021038777 @default.
• W3135926707 creator A5021195395 @default.
• W3135926707 creator A5031872120 @default.
• W3135926707 creator A5036553810 @default.
• W3135926707 creator A5061163790 @default.
• W3135926707 creator A5083334581 @default.
• W3135926707 creator A5087211784 @default.
• W3135926707 creator A5089983966 @default.
• W3135926707 date "2021-03-01" @default.
• W3135926707 modified "2023-09-30" @default.
• W3135926707 title "P76.39 Acquired Resistance Mechanisms in T790M-Positive Advanced NSCLC Tested by Non-Invasive Molecular Testing (NIMT) and Their Clinical Relevance" @default.
• W3135926707 doi "https://doi.org/10.1016/j.jtho.2021.01.1096" @default.
• W3135926707 hasPublicationYear "2021" @default.
• W3135926707 type Work @default.
• W3135926707 sameAs 3135926707 @default.
• W3135926707 citedByCount "0" @default.
• W3135926707 crossrefType "journal-article" @default.
• W3135926707 hasAuthorship W3135926707A5000749939 @default.
• W3135926707 hasAuthorship W3135926707A5008073664 @default.
• W3135926707 hasAuthorship W3135926707A5021038777 @default.
• W3135926707 hasAuthorship W3135926707A5021195395 @default.
• W3135926707 hasAuthorship W3135926707A5031872120 @default.
• W3135926707 hasAuthorship W3135926707A5036553810 @default.
• W3135926707 hasAuthorship W3135926707A5061163790 @default.
• W3135926707 hasAuthorship W3135926707A5083334581 @default.
• W3135926707 hasAuthorship W3135926707A5087211784 @default.
• W3135926707 hasAuthorship W3135926707A5089983966 @default.
• W3135926707 hasBestOaLocation W31359267071 @default.
• W3135926707 hasConcept C104317684 @default.
• W3135926707 hasConcept C121608353 @default.
• W3135926707 hasConcept C126322002 @default.
• W3135926707 hasConcept C143998085 @default.
• W3135926707 hasConcept C2775999482 @default.
• W3135926707 hasConcept C2776256026 @default.
• W3135926707 hasConcept C2777626846 @default.
• W3135926707 hasConcept C2777930144 @default.
• W3135926707 hasConcept C2781182431 @default.
• W3135926707 hasConcept C36823959 @default.
• W3135926707 hasConcept C501734568 @default.
• W3135926707 hasConcept C54355233 @default.
• W3135926707 hasConcept C71924100 @default.
• W3135926707 hasConcept C86803240 @default.
• W3135926707 hasConceptScore W3135926707C104317684 @default.
• W3135926707 hasConceptScore W3135926707C121608353 @default.
• W3135926707 hasConceptScore W3135926707C126322002 @default.
• W3135926707 hasConceptScore W3135926707C143998085 @default.
• W3135926707 hasConceptScore W3135926707C2775999482 @default.
• W3135926707 hasConceptScore W3135926707C2776256026 @default.
• W3135926707 hasConceptScore W3135926707C2777626846 @default.
• W3135926707 hasConceptScore W3135926707C2777930144 @default.
• W3135926707 hasConceptScore W3135926707C2781182431 @default.
• W3135926707 hasConceptScore W3135926707C36823959 @default.
• W3135926707 hasConceptScore W3135926707C501734568 @default.
• W3135926707 hasConceptScore W3135926707C54355233 @default.
• W3135926707 hasConceptScore W3135926707C71924100 @default.
• W3135926707 hasConceptScore W3135926707C86803240 @default.
• W3135926707 hasIssue "3" @default.
• W3135926707 hasLocation W31359267071 @default.
• W3135926707 hasOpenAccess W3135926707 @default.
• W3135926707 hasPrimaryLocation W31359267071 @default.
• W3135926707 hasRelatedWork W2007661090 @default.
• W3135926707 hasRelatedWork W2024276281 @default.
• W3135926707 hasRelatedWork W2549506770 @default.
• W3135926707 hasRelatedWork W2600318014 @default.
• W3135926707 hasRelatedWork W2765285169 @default.
• W3135926707 hasRelatedWork W2896568882 @default.
• W3135926707 hasRelatedWork W2907478003 @default.
• W3135926707 hasRelatedWork W2985223206 @default.
• W3135926707 hasRelatedWork W3137075329 @default.
• W3135926707 hasRelatedWork W4245657304 @default.
• W3135926707 hasVolume "16" @default.
• W3135926707 isParatext "false" @default.
• W3135926707 isRetracted "false" @default.
• W3135926707 magId "3135926707" @default.
• W3135926707 workType "article" @default.